The company is committed to the legal development of regulated, safe & effective therapies, and in educating the public and medical profession as to the efficacy of psychedelic protocols when clinically administered in the optimum set and setting.
To view the Interview, please visit:
https://www.abnnewswire.net/press/en/104434/entheon
About Entheon Biomedical:
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products ("DMT Products") for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in
Contact:
Telephone: +1 (778) 919-8615
Joe@entheonbiomedical.com
https://entheonbiomedical.com/
Copyright (C) 2021 ABN Newswire. All rights reserved., source